OGN · NYSE
Organon & Co. (OGN) Stock Price & Fundamentals
Organon & Co. (OGN) closed at $371.63 on Oct 9, 2026, down 1.27% from the previous close of $376.41.
Share price, past year
1Y −7.06%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $371.63 |
| Sep 30, 2026 | $381.65 |
| Aug 31, 2026 | $345.02 |
| Jul 31, 2026 | $360.19 |
| Jun 30, 2026 | $377.66 |
| May 29, 2026 | $388.53 |
| Apr 30, 2026 | $405.17 |
| Mar 31, 2026 | $418.09 |
| Feb 27, 2026 | $407.02 |
| Jan 30, 2026 | $409.24 |
| Dec 31, 2025 | $423.44 |
| Nov 28, 2025 | $417.74 |
| Oct 31, 2025 | $409.63 |
Key statistics
- Market cap
- $97.59B
- P/E (TTM)
- 476.5
- EPS (TTM)
- $0.78
- Revenue (TTM)
- $6.13B
- Net income (TTM)
- $209.00M
- Shares outstanding
- 262.6M
- Dividend yield
- 0.02%
- 52-week range
- $338.88 – $442.65
Organon & Co.'s market cap is $97.59B, based on a share price of $371.63 and 262.6M shares outstanding as of Jun 30, 2026.
Financials
Organon & Co. reported revenue of $6.22B for fiscal 2025, down 2.92% from fiscal 2024.
Organon & Co. earned net income of $187.00M in fiscal 2025, a net margin of 3.0%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $6.22B | −2.9% | $187.00M | 3.0% | $0.72 | $538.00M |
| FY2024ended Dec 31, 2024 | $6.40B | +2.2% | $864.00M | 13.5% | $3.33 | $764.00M |
| FY2023ended Dec 31, 2023 | $6.26B | +1.4% | $1.02B | 16.3% | $3.99 | $548.00M |
| FY2022ended Dec 31, 2022 | $6.17B | −2.1% | $917.00M | 14.9% | $3.59 | $662.00M |
| FY2021ended Dec 31, 2021 | $6.30B | −3.5% | $1.35B | 21.4% | $5.31 | — |
| FY2020ended Dec 31, 2020 | $6.53B | −16.0% | $2.16B | 33.1% | $8.52 | — |
| FY2019ended Dec 31, 2019 | $7.78B | — | $3.22B | 41.4% | $12.69 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $1.56B | $108.00M | $0.40 |
| Q1 FY2026ended Mar 31, 2026 | $1.46B | $146.00M | $0.55 |
| Q4 FY2025ended Dec 31, 2025 | $1.51B | −$205.00M | −$0.78 |
| Q3 FY2025ended Sep 30, 2025 | $1.60B | $160.00M | $0.61 |
| Q2 FY2025ended Jun 30, 2025 | $1.59B | $145.00M | $0.56 |
| Q1 FY2025ended Mar 31, 2025 | $1.51B | $87.00M | $0.33 |
| Q4 FY2024ended Dec 31, 2024 | $1.59B | $109.00M | $0.42 |
| Q3 FY2024ended Sep 30, 2024 | $1.58B | $359.00M | $1.38 |
Company profile
- Name
- Organon & Co.
- Ticker
- OGN
- Exchange
- NYSE
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 30 Hudson Street, Fl 33, Jersey City, NJ 07302
- Fiscal year ends
- December
- SEC CIK
- 0001821825
Recent SEC filings
- Jul 31, 2026
- Jul 31, 2026
- Jul 23, 2026
- Jul 17, 2026
- Jun 11, 2026
- May 4, 2026
- Apr 30, 2026
- Apr 27, 2026
Frequently asked questions
What is Organon & Co.'s stock price?
Organon & Co. (OGN) closed at $371.63 on Oct 9, 2026, down 1.27% from the previous close of $376.41.
What is Organon & Co.'s market cap?
Organon & Co.'s market cap is $97.59B, based on a share price of $371.63 and 262.6M shares outstanding as of Jun 30, 2026.
How much revenue does Organon & Co. make?
Organon & Co. reported revenue of $6.22B for fiscal 2025, down 2.92% from fiscal 2024.
What is OGN's P/E ratio?
Organon & Co.'s price-to-earnings ratio is 476.5, based on trailing twelve-month diluted EPS of $0.78.
Does Organon & Co. pay a dividend?
Yes. Organon & Co. declared $0.08 per share in dividends over the last four quarters, a yield of 0.02%.
Sources and methodology
Fundamentals come from Organon & Co.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures